Effectiveness of Aripiprazole Long-acting Injection in Recent Onset and Chronic Schizophrenia Patients

• Status: Completed
• Trial end date: 2020-09-30
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is to investigate the effectiveness of Aripiprazole long-acting injection in recent onset and chronic schizophrenia patients

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chonbuk National University Hospital
• Collaborator: Otsuka Pharmaceutical Co., Ltd.
• Treatments: Aripiprazole

Criteria

Inclusion Criteria:

• Patients diagnosed with schizophrenia according to DSM-5 diagnostic standards

• men and women aged 19 and under 60

• a person who is being given an atypical antipsychotic.

• Patients should be able to reasonably cooperate with the questionnaire to be used for the study

• a person who fully understands the purpose of the study and signs the consent

• stable outpatient before screening without changing the volume of antipsychotics for at least two weeks

Exclusion Criteria:

• a person who has a serious and unstable physical condition either now or in the past

• A fertile woman who is currently pregnant or breastfeeding, or who is either unwilling or unable to use acceptable contraception until the clinical trial is complete.

• a person suffering from severe drug allergies or complex and severe drug reactions

• Patients who have taken clozapine in the last 60 days

• subjects showing significant risk of suicide or significant risk of violent behavior based on past history or investigator's judgment